Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed strong Phase 2 results in relapsed/refractory AML, surpassing 20% overall ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...

Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. The updated ...